NE3107 is an oral, blood-brain barrier-crossing small molecule compound with anti-inflammatory, insulin-sensitizing and ERK-binding properties.

January 20, 2022 / Bio Valley BIOON/--BioVie recently announced that the first patient has been evaluated in the Phase 2 clinical study NM201 (NCT05083260) evaluating the potential pro-motor effects of NE3107 in patients with Parkinson's disease (PD). Drug treatment was performed.

Preclinical studies have shown that NE3107 is as effective as levodopa in improving motor symptoms. When NE3107 was administered in combination with levodopa, the combination showed greater promotor activity than either NE3107 or levodopa administered alone. In addition, NE3107 in combination with levodopa reduced the severity of levodopa-induced dyskinesia (LID), but not the beneficial effects of the drug on motor symptoms. In animal experiments, NE3107-treated monkeys retained approximately twice as many dopaminergic neurons as vehicle-treated monkeys, suggesting that NE3107 may have neuroprotective properties.

Neuroinflammation, insulin resistance, and oxidative stress are common features of major neurodegenerative diseases, including Parkinson's disease (PD), Alzheimer's disease (AD), frontotemporal dementia, and amyotrophic lateral sclerosis (ALS).

NE3107 is an oral, blood-brain barrier-crossing small molecule compound with anti-inflammatory, insulin-sensitizing and ERK-binding properties that selectively inhibits ERK and NFκB-stimulated inflammation. No major safety signals were observed in the nonclinical safety studies, and the adverse event profile of NE3107 did not differ from that of placebo in clinical studies conducted to date.

NE3107's potential to inhibit neuroinflammation and insulin resistance is the basis for BioVie's testing of the molecule in AD and PD patients. The company is currently conducting a Phase 3 clinical trial evaluating NE3107 in Alzheimer's disease (AD), with results expected by the end of 2022.

Chemical structural formula of NE3107 (picture from the literature PMID: 34251287)

NM201 is a double-blind, placebo-controlled, safety, tolerability and pharmacokinetic study in Parkinson's disease (PD) patients who will receive carbidopa/levodopa , while receiving NE3107 or placebo treatment. In the study, 40 PD patients in the "OFF state" will be randomly assigned in a 1:1 ratio to placebo, NE3107 (20 mg, twice daily) for 28 days.

The safety assessment will look at standard measures of patient health and the potential for drug interactions affecting levodopa pharmacokinetics and activity. Exploratory efficacy assessments will use Parkinson's and Movement Disorders Society International (MDS)-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts 1-3, ON/OFF Diary, Non-Motor Symptom Scale Table (Non-Motor Symptom Scale) for measurement. Top-line results are expected in mid-2022. (Bioon.com)